Meta Platforms
META
Taiwan Semiconductor
TSM
Amazon
AMZN
Apple
AAPL
NVIDIA
NVDA
US Stock MarketDetailed Quotes
ADIL Adial Pharmaceuticals
- 1.1100
- +0.0400+3.74%
Close Dec 3 16:00 ET
- 1.0700
- -0.0400-3.60%
Post 20:01 ET
7.11MMarket Cap-335P/E (TTM)
1.1800High1.0400Low904.38KVolume1.1100Open1.0700Pre Close1.02MTurnover15.19%Turnover RatioLossP/E (Static)6.41MShares4.169952wk High1.21P/B6.61MFloat Cap0.765052wk Low--Dividend TTM5.95MShs Float236.0000Historical High--Div YieldTTM13.08%Amplitude0.7650Historical Low1.1220Avg Price1Lot Size
Adial Pharmaceuticals Stock Forum
Sign in to post a comment
Note: The presence of 30 stock picks reflects the reality that not all stocks respond to their press releases immediately. For instance, today’s market activity saw certain high-performing stocks overshadow promising PRs, suggesting that it may take a day, several days, or even a week for the market to fully digest and react. I encourage you to save the watchlist I p...
7
3
1
$Adial Pharmaceuticals (ADIL.US)$
Adial
Pharmaceuticals Tells Benzinga Co. Granted Key U.S. Patent For The Treatment Of Alcohol And Drug Dependence Based On Expanded Genotype Combinations
Adial
Pharmaceuticals Tells Benzinga Co. Granted Key U.S. Patent For The Treatment Of Alcohol And Drug Dependence Based On Expanded Genotype Combinations
2
$Adial Pharmaceuticals (ADIL.US)$ EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga Co. Granted Key U.S. Patent For The Treatment Of Alcohol And Drug Dependence Based On Expanded Genotype Combinations
$Adial Pharmaceuticals (ADIL.US)$ ✨👌 this one needs magic dust too
$Adial Pharmaceuticals (ADIL.US)$ Benzinga· 2 mins ago
EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Marks Final Study Needed for the Upcoming FDA Meeting for the Phase 3 Study Design and Ongoing Partnership Discussions'
EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Marks Final Study Needed for the Upcoming FDA Meeting for the Phase 3 Study Design and Ongoing Partnership Discussions'
1
$Adial Pharmaceuticals (ADIL.US)$ Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
GLEN ALLEN, Va., Oct. 23, 2024 — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel i...
GLEN ALLEN, Va., Oct. 23, 2024 — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel i...
$Adial Pharmaceuticals (ADIL.US)$ EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Expands Patent Estate Covering Adial's Unique Molecular Genetic Approach to Diagnosing and Potentially Treating Alcohol and Drug Dependence'
$Adial Pharmaceuticals (ADIL.US)$
Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Continuing to consolidate under 1.04. Keep the open GAP on watch next week for another test of .90. Until over 1.05 just chop.
Larger Image: tradingview.com...
$Adial Pharmaceuticals (ADIL.US)$
Larger Image: tradingview.com...
$Adial Pharmaceuticals (ADIL.US)$
4
$Adial Pharmaceuticals (ADIL.US)$
Adial Pharmaceuticals (NASDAQ: ADIL) has announced the completion of patient dosing in the pharmacokinetics study of AD04, their lead investigational treatment for Alcohol Use Disorder (AUD). The study, involving 30 healthy adult volunteers, aims to optimize dosing and enhance efficacy and safety for AUD patients. Topline results are expected in the fourth quarter of 2024.
The single-center open-label study compares the pharmacokinetic profile of AD04 at a 0.33 ...
Adial Pharmaceuticals (NASDAQ: ADIL) has announced the completion of patient dosing in the pharmacokinetics study of AD04, their lead investigational treatment for Alcohol Use Disorder (AUD). The study, involving 30 healthy adult volunteers, aims to optimize dosing and enhance efficacy and safety for AUD patients. Topline results are expected in the fourth quarter of 2024.
The single-center open-label study compares the pharmacokinetic profile of AD04 at a 0.33 ...
No comment yet
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
AhmadFH : Thanks Jag
71580478 : love it, thanks! what do you think about SHIM?
JMK47 : thanks for all your effort